Author: Benzinga Newsdesk | August 11, 2025 05:01am
Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.40) by 25.63 percent. This is a 92.31 percent decrease over losses of $(0.26) per share from the same period last year.